SIGA Technologies

E521269

SIGA Technologies is a pharmaceutical company specializing in the development of antiviral treatments, particularly for smallpox and other orthopoxvirus infections.

All labels observed (2)

Label Occurrences
NASDAQ:SIGA 1
SIGA Technologies canonical 1

How this entity was disambiguated

Statements (46)

Predicate Object
instanceOf pharmaceutical company
public company
countryOfIncorporation United States
develops ST-246
TPOXX
tecovirimat
drugTargetPathogen monkeypox virus
orthopoxviruses
variola virus
focusesOn biodefense
health security
foundedIn 1995
hasBrandName TPOXX
hasBusinessModel development of medical countermeasures for biodefense
hasCollaboration U.S. Biomedical Advanced Research and Development Authority
hasContractWith U.S. Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services
hasOrphanDrugDesignation tecovirimat
hasRegulatoryApproval European Medicines Agency
Health Canada
U.S. Food and Drug Administration
United Kingdom Medicines and Healthcare products Regulatory Agency
headquartersCountry United States
headquartersLocation New York City
headquartersState New York
industry biotechnology
pharmaceuticals
listedOn NASDAQ
notableProduct ST-246
TPOXX
tecovirimat
primaryTherapeuticArea infectious diseases
viral infections
productIndication monkeypox
orthopoxvirus infections
smallpox
researchFocus orthopoxvirus countermeasures
small-molecule antivirals
servesCustomer government agencies
public health authorities
specializesIn antiviral treatments
orthopoxvirus infections
smallpox therapeutics
supplies U.S. Strategic National Stockpile
therapeuticModality oral antiviral drugs
tradedAs NASDAQ:SIGA
linked to: SIGA Technologies

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

MacAndrews & Forbes hasInvestmentIn SIGA Technologies
SIGA Technologies tradedAs NASDAQ:SIGA
linked to: SIGA Technologies